We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




X-Ray Crystallography Findings Aid Discovery of New Drugs

By LabMedica International staff writers
Posted on 18 Apr 2017
Print article
Image: Crystal structures of Mtb RNAP bound to rifampin (left) and Mtb RNAP bound to an AAP (right) show the Mtb RNAP interactions. Gray ribbons, Mtb RNAP backbone; gray, cyan, and green sticks, Mtb RNAP, rifampin, and AAP carbon atoms; red and blue sticks, oxygen and nitrogen atoms; green mesh, mFo-Fc electron density omit map; BH, Mtb RNAP bridge helix (Photo courtesy of Wei Lin and Richard H. Ebright, Rutgers University).
Image: Crystal structures of Mtb RNAP bound to rifampin (left) and Mtb RNAP bound to an AAP (right) show the Mtb RNAP interactions. Gray ribbons, Mtb RNAP backbone; gray, cyan, and green sticks, Mtb RNAP, rifampin, and AAP carbon atoms; red and blue sticks, oxygen and nitrogen atoms; green mesh, mFo-Fc electron density omit map; BH, Mtb RNAP bridge helix (Photo courtesy of Wei Lin and Richard H. Ebright, Rutgers University).
Sensitive X-ray crystallography techniques were used to determine the three-dimensional (3D) molecular structure of the Mycobacterium tuberculosis enzyme RNA polymerase (Mtb RNAP) alone and when bound to the present first-line anti-tuberculosis drug rifampin.

M. tuberculosis (Mtb) is the causative agent of tuberculosis (TB), which annually kills about 1.8 million people worldwide.

Rifampin is used for the treatment of tuberculosis in combination with other antibiotics, such as pyrazinamide, isoniazid, and ethambutol. For the treatment of tuberculosis, rifampin is administered daily for at least six months. Combination therapy is utilized both to prevent the development of resistance and to shorten the length of treatment. Rifampin inhibits bacterial DNA-dependent RNA synthesis by inhibiting bacterial DNA-dependent RNA polymerase. Resistance to rifampin develops quickly when it is used without another antibiotic. Efforts to circumvent the development of resistance to rifampin have been hampered by the absence of structural information for Mtb RNAP, making rational, structure-based drug discovery for Mtb RNAP impossible.

In the current study, investigators at Rutgers University used X-ray crystallography to establish the crystal structures of Mtb RNAP, alone and in complex with rifampin at 3.8 - 4.4 Angstrom resolution. Results published in April 6, 2017, online edition of the journal Molecular Cell revealed an Mtb-specific structural module of Mtb RNAP and established that rifampin functioned by a steric-occlusion mechanism that prevented extension of RNA.

The investigators also reported the discovery of non-rifampin-related compounds -Nalpha-aroyl-N-aryl-phenylalaninamides (AAPs) - that potently and selectively inhibited Mtb RNAP and Mtb growth, and they described crystal structures of Mtb RNAP in complex with AAPs. AAPs were found to bind to a different site on Mtb RNAP than rifampin, exhibited no cross-resistance with rifampin, functioned additively when co-administered with rifampin, and suppressed resistance emergence when co-administered with rifampin.

"The structure of Mtb RNAP has been the "Holy Grail" for TB drug discovery targeting Mtb RNAP," said senior author Dr. Richard H. Ebright, professor of chemistry and chemical biology at Rutgers University. "AAPs represent an entirely new class of Mtb RNAP inhibitors and are, without question, the most promising Mtb RNAP inhibitors for anti-TB drug development since rifampin. We are very actively pursuing AAPs. We have synthesized and evaluated more than 600 novel AAPs and have identified AAPs with high potencies and favorable intravenous and oral pharmacokinetics."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.